Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327267 | 0.92 | GAA (0.44) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL24972998 | 0.91 | GAA (0.42) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL24849898 | 0.90 | MAPT (0.41) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL25753951 | 0.85 | GAA (0.37) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL26068748 | 0.85 | MAPT (0.43) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL26068684 | 0.85 | GAA (0.41) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL24023162 | 0.85 | MAPT (0.40) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL26049672 | 0.84 | ALDH1A1 (0.46) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL22327237 | 0.84 | ALDH1A1 (0.37) | MAPTGAAMAOBALDH1A1CHRM2 | |
| SCHEMBL24970907 | 0.84 | KAT6A (0.38) | MAPTGAAMAOBALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | NUDT1, RNMT, ADAR | MAPT 4693/4885GAA 668/4885MAOB 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.